The Influence of Selenium on Biomarkers of Prostate Cancer Risk

Trial Information

The Influence of Selenium on Biomarkers of Prostate Cancer Risk

We will conduct a double-blind, randomized, placebo-controlled clinical study of selenium
supplementation in the form of L-selenomethionine (SM)(200 µg/day) and selenium-enriched
yeast (SY) (200 µg/day and 285 µg/day) for 12 months; the 285 µg/day SY is selected to
deliver an equivalent selenium as in 200 µg/day SM to healthy men. Some time during the 12
months study period, all groups will take the placebo pill for at least 3 months. The
subjects will compose of African Americans, Hispanics, and white Americans in different age
groups defined as follows: Young adult (20-39 year old), Matured adult (40-59 year old), Old
adult (60-79 year old). The Young adult group will serve as a reference group and will be
used to validate our previous results. The variability of SM in SY that will be used here is
less than 3% and it accounts for 70.5% of the SM content in SY.